Filters

Anti-PARK9/ATP13A2 (Polyclonal), ALEXA Fluor 594

Anti-PARK9/ATP13A2 (Polyclonal), ALEXA Fluor 594 size: 100 microliters 489

Price 489
Size 100 microliters
TypeConjugated Primary Antibody
Conjugated with 594, ALEXA FLUOR®
Host organismRabbit (Oryctolagus cuniculus)
Target Protein/PeptidePARK9/ATP13A2
SpecificityThis antibody reacts specifically with PARK9/ATP13A2
ModificationNo modification has been applied to this antibody
Modification siteNone
ClonalityPolyclonal Antibody
ClonePolyclonal Antibodies
Concentration1ug per 1ul
Subcellular locationsExtracellular
Antigen SourceKLH conjugated synthetic peptide derived from human ATP13A2
Gene IDN/A
Swiss ProtN/A
Applications IF(IHC-P), FCM
Applications with corresponding dilutions IF(IHC-P)(1:50-200), FCM(1:20-100)
Cross reactive species Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens)
Cross Reactive Species details However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species
Background information ATP13A2 functions to catalyze the conversion of ATP to ADP and a free phosphate, Defects in the gene encoding ATP13A2 are the cause of Kufor-Rakeb syndrome (KRS), Expressed as multiple alternative spliced isoforms, The ATP13A2 gene maps to human chromosome 1, a rare hereditary type of Parkinsonâ, contains over 3, thereby participating in the active transport of ions across cellular membranes, which spans 260 million base pairs, &euro, &trade, 000 genes and comprises nearly 8% of the human genome, 180 amino acid multi-pass membrane protein that belongs to the P5 subfamily of ATPases which play an important role in the transportation of inorganic cations, ATP13A2 is a 1, s disease that exhibits juvenile onset and is characterized by neurodegeneration and dementia
Purification methodPurified by Protein A
Storage 50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA
Excitation emission590nm/617nm
Synonyms HSA9947 CLN12
Also known asPARK9/ATP13A2 Polyclonal Antibody
Other nameAnti-PARK9/ATP13A2 Polyclonal
Advisory For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody
PropertiesFor facs or microscopy Alexa 1 conjugate
ConjugationAlexa Fluor
GroupPolyclonals and antibodies
About The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera, immunohistochemistry on frozen slices or parrafin fixed tissues, Polyclonals can be used for Western blot
Gene targetPARK9/ATP13A2
Short nameAnti-PARK9/ATP13A2 (Polyclonal) Fluor 594
Technique Pabs are a collection of immunoglobulin , Polyclonal antibodies , each identifying a different , whereas , (pAbs) are mostly rabbit or goat , B cells, Polyclonal, antibodies , antigen, come from a single N cell lineage, epitope, molecules that react against a specific , monoclonal antibodies , that are secreted by different 
LabelALEXA
Alternative name ALEXA Fluor 594, antibody to-PARK9/ATP13A2 (polyclonal)
Alternative techniquepolyclonals
Identity 30213
Gene ATP13A2
Long gene name ATPase 13A2
Synonyms gene PARK9
Synonyms gene name Parkinson disease (autosomal recessive) 9 (Kufor-Rakeb syndrome) ATPase type 13A2
Locus 1p36, 13
Discovery year 2005-01-12
GenBank acession AL354615
Entrez gene record 23400
Pubmed identfication 15381061 16964263
RefSeq identity NM_022089
Classification Parkinson disease associated genes ATPase orphan transporters
Havana BLAST/BLAT OTTHUMG00000002293
Locus Specific Databases LRG_834

Subscribe to our Newsletter